查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2015054

微創青光眼手術器械市場：2026-2032年全球市場預測（依器械類型、手術部位、適應症、手術入路、手術方法、植入材料、器械分類、支付方式、病患類型、最終用戶和分銷管道分類）

Minimally Invasive Glaucoma Surgery Devices Market by Device Type, Surgical Site, Indication, Surgical Approach, Procedure Type, Implant Material, Device Class, Payment Method, Patient Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年微創青光眼手術器材市值為 6.0169 億美元，預計到 2025 年將成長至 6.3551 億美元，複合年成長率為 5.80%，到 2032 年將達到 9.448 億美元。

主要市場統計數據
基準年 2024 6.0169億美元
預計年份：2025年 6.3551億美元
預測年份 2032 9.448億美元
複合年成長率 (%) 5.80%

本文清晰簡潔地概述了微創青光眼手術 (MIGS) 中使用的設備、其臨床原理、推動其採用的因素以及其對臨床實踐的影響。

微創青光眼手術（MIGS）器械的出現徹底改變了青光眼的治療方式，為傳統濾過手術提供了一種更安全、創傷更小的替代方案。這些技術優先考慮快速康復、降低手術全期風險以及早期干預疾病進展，從而滿足了臨床醫生對療效和安全性之間平衡的需求。 MIGS 的普及應用得益於不斷累積的證據、器械設計的持續改進以及臨床指南的更新，這些指南日益認可 MIGS 在白內障手術患者以及特定適應症中的應用價值。

技術進步、不斷發展的臨床證據和醫療保健系統優先事項如何重塑微創青光眼手術 (MIGS) 市場和交付流程。

微創胃鏡手術（MIGS）領域正經歷著一場變革，其驅動力包括技術進步、不斷擴大的臨床證據以及強調門診治療和價值醫療的機構壓力。植入形狀和輸送系統的改進使植入更加便捷，併發症發生率降低。因此，外科醫師的信心增強，適用患者範圍也隨之擴大。同時，手術技術的創新，特別是白內障和青光眼聯合手術的普及，正在為早期療育開闢新的途徑，並模糊了專科眼科和全科醫療之間的傳統界限。

本研究評估了 2025 年關稅措施的累積影響將如何重塑微創青光眼治療設備製造商的採購、製造地和籌資策略。

2025年推出的新關稅政策和貿易措施對支持醫療設備生產的全球供應鏈造成了重大打擊，影響了零件、原料和子組件的採購。對於依賴鎳鈦合金、鈦等特殊金屬以及各種聚合物材料的微創青光眼手術（MIGS）器械而言，關稅措施的累積影響正在推高投入成本，迫使製造商重新考慮其籌資策略。為此，許多公司正在加速供應商多元化、將關鍵製造流程外包以及對高價值零件進行垂直整合，以降低進口稅和跨境物流波動的風險。

一項全面的、以細分為導向的分析，將醫療設備類型、臨床適應症、外科技術、材料、最終用戶和分銷管道與策略重點聯繫起來。

精細的細分觀點揭示了產品設計、臨床定位和商業策略中存在的微妙機會和限制。器械類型包括施萊姆氏管支架和擴張器、結膜下微引流管、脈絡膜上腔微引流管和小梁網旁路支架。後者可進一步分為多支架系統和單支架系統。每種器械都有其獨特的療效特徵、植入技術和實證途徑，這些因素都會影響其市場接受度。針對不同適應症的臨床效用也各不相同，例如隅角閉鎖性青光眼、先天性青光眼、原發性開放性青光眼和續發性青光眼，因此需要針對特定患者群體進行個人化的臨床試驗和行銷策略，以檢驗器材的安全性和有效性。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和市場進入考慮因素，為制定監管、商業和營運策略提供了重要的見解。

區域趨勢持續影響全球的產品策略、監管路徑和商業性促進因素。在美洲，嚴格的監管和完善的報銷機制使得擁有可靠臨床證據支持的醫療設備能夠儘早實現商業化，而門診手術中心的普及也為微創青光眼手術（MIGS）的推廣應用創造了有利的運作環境。此外，能夠顯著減輕術後負擔的創新技術在該地區更受青睞，手術簡便性和可重複的治療效果是商業性成功的關鍵。放眼東方，歐洲、中東和非洲（EMEA）地區呈現出管理體制、支付方結構和採購慣例的複雜格局。雖然一些市場採用統一的監管標準以促進跨境准入，但其他市場則需要特定區域的臨床數據和客製化的成本核算模型，這需要製定區域性的商業策略。

競爭定位、臨床證據策略和策略夥伴關係如何決定微創青光眼治療設備 (MIGS) 製造商的領導地位和差異化優勢。

微創手術器材 (MIGS) 領域的競爭動態是由成熟的醫療設備製造商、專注於眼科領域的公司以及致力於差異化技術方案的新興Start-Ups之間的互動所塑造的。大型公司著重完善的臨床試驗和上市後監測，以確定其療效和長期安全性。同時，小規模的創新者則利用諸如新型植入形狀、軟性聚合物材料或符合人體工學的輸送系統等特定細分領域，以期儘早獲得臨床應用。策略活動通常著重於透過合作加速夥伴關係、透過共同開發契約整合手術平台以及透過選擇性收購來擴展產品組合，從而涵蓋互補的手術方法。

為製造商、醫療保健系統和經銷商提供可操作的、優先的和策略性的行動，以加速微創青光眼手術 (MIGS) 的採用、產生證據並加強供應鏈的韌性。

微創青光眼手術（MIGS）生態系統的領導者應優先考慮能夠平衡臨床價值和營運韌性的實際可行的優先事項。首先，應優先產生臨床證據，以檢驗與替代手術方法相比的療效，並證明其在聯合治療和單藥治療適應症中的益處。這將有助於加強與保險公司和醫院藥物選擇委員會的諮詢。其次，應透過供應商多元化、考慮高風險組件的在地化生產以及降低貿易中斷和關稅波動風險的庫存策略來最佳化供應鏈。

採用透明且以證據為基礎的調查方法，結合與專家的初步訪談、系統性的臨床審查和檢驗，以檢驗策略性發現。

本分析整合了第一手和第二手調查方法，以確保獲得平衡且基於證據的觀點。第一手研究包括對眼科醫師、醫院採購經理和醫療設備研發專家進行結構化訪談，以收集有關手術偏好、器械選擇標準和供應鏈考量等方面的真實資訊。第二手研究則對同行評審的臨床文獻、監管指導文件和公開的手術指南進行了系統性回顧，以檢驗療效、安全性和核准途徑要求。結合這些方法，我們對臨床和商業性動態有了多層次的理解。

這是策略要點的簡要總結，重點闡述了證據、商業化和營運韌性如何塑造 MIGS 的長期成功。

微創青光眼手術器材是眼科醫學領域一個成熟但又快速發展的領域，漸進式創新、臨床證據和營運準備共同塑造其應用軌跡。器械類型、手術入路、材料選擇和終端用戶環境等因素相互作用，構成了一個複雜的市場格局。在此背景下，專注於臨床研發和靈活執行商業性策略的企業將獲得豐厚回報。在不斷變化的供應鏈壓力和政策趨勢下，企業能否靈活調整採購、生產和培訓計劃，將日益成為區分韌性企業和易受衝擊企業的關鍵因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 微創青光眼手術器械市場：依器械類型分類

  • 消融工具
  • 導管
  • 基於管腔的分流器
    • 固定流明
    • 流量控制類型
  • 支架/擴張器
  • 支架

第9章 微創青光眼手術器械市場：依手術部位分類

  • 睫狀體
  • 施萊姆管
  • 結膜下間隙
  • 脈絡膜上腔
  • 小梁網

第10章 微創青光眼手術器材市場：依適應症分類

  • 隅角閉鎖性青光眼
  • 先天性青光眼
  • 原發性開放性青光眼
  • 續發性青光眼

第11章 微創青光眼手術器械市場：依手術方式分類

  • 外部方法
  • 內部方法

第12章 微創青光眼手術器械市場：依手術方法分類

  • 與白內障手術合併使用
  • 單次手術

第13章 微創青光眼手術器械市場：依植入材料分類

  • 金屬
    • 鎳鈦諾
    • 鈦
  • 聚合物
    • 明膠
    • 聚醚碸
    • 聚醯亞胺
    • 矽酮

第14章 微創青光眼手術器械市場：依器械分類

  • 嵌入式
  • 非嵌入式類型

第15章 微創青光眼手術器材市場：依支付方式分類

  • 保險範圍
  • 自費

第16章 微創青光眼手術器械市場：依病患類型分類

  • 兒童
  • 成人

第17章 微創青光眼手術器材市場：依易用性分類

  • 可重複使用的
  • 一次性的

第18章 微創青光眼手術器械市場：依最終用戶分類

  • 門診手術中心
  • 眼科診所
  • 專科眼科醫院

第19章 微創青光眼手術器械市場：依通路分類

  • 離線
  • 線上

第20章 微創青光眼手術器材市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第21章 微創青光眼手術器材市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第22章 微創青光眼手術器材市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第23章：美國微創青光眼手術器材市場

第24章：中國微創青光眼手術器材市場

第25章 競爭情勢

  • 2024年市場集中度分析
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2024 年
  • 2024年產品系列分析
  • 基準分析，2024 年
  • AbbVie Inc.
  • Alcon Vision LLC
  • Bausch+Lomb Corp.
  • BVI Medical, Inc.
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • Glaukos Corporation
  • Haag-Streit Group by Metall Zug AG
  • Iridex Corporation
  • iSTAR Medical
  • Johnson & Johnson Services, Inc.
  • Lumibird Medical
  • New World Medical, Inc.
  • Nova Eye Medical Limited
  • Oertli Instrumente AG
  • Santen Pharmaceutical Co., Ltd.
Product Code: MRR-036C5CF3A869

The Minimally Invasive Glaucoma Surgery Devices Market was valued at USD 601.69 million in 2024 and is projected to grow to USD 635.51 million in 2025, with a CAGR of 5.80%, reaching USD 944.80 million by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 601.69 million
Estimated Year [2025] USD 635.51 million
Forecast Year [2032] USD 944.80 million
CAGR (%) 5.80%

A clear and concise overview of minimally invasive glaucoma surgery devices, their clinical rationale, adoption drivers, and implications for clinical practice

Minimally invasive glaucoma surgery (MIGS) devices have reshaped therapeutic strategies for glaucoma management by offering safer, less invasive alternatives to traditional filtration surgeries. These technologies prioritize rapid recovery, reduced perioperative risk, and suitability for earlier intervention in the disease continuum, thereby aligning with clinician preferences for procedures that balance efficacy and safety. Adoption has been driven by an expanded evidence base, iterative device design improvements, and shifting clinical guidelines that increasingly recognize the role of MIGS for patients undergoing cataract surgery as well as for select standalone indications.

As a consequence, stakeholders across clinical, commercial, and regulatory domains must reassess investment priorities, training programs, and supply-chain design to respond to wider MIGS adoption. Surgeons are refining patient selection criteria and surgical workflows, while health systems evaluate resource allocation across ambulatory surgery centers and specialty clinics. Together, these dynamics underscore the need for a holistic market view that connects device innovation, procedural strategy, and operational readiness to realize the full value proposition of MIGS technology.

How technological refinement, evolving clinical evidence, and health system priorities are reshaping the minimally invasive glaucoma surgery market and care delivery pathways

The MIGS landscape is undergoing transformative shifts catalyzed by technological refinement, expanded clinical evidence, and systemic pressures that favor outpatient and value-based care. Iterations in implant geometry and delivery systems have improved ease of implantation and lowered complication rates, which in turn reinforce surgeon confidence and broaden candidate profiles. In parallel, procedural innovation-particularly the normalization of combined cataract and glaucoma procedures-has created new pathways for earlier intervention while blurring traditional boundaries between subspecialty and general ophthalmic practice.

Concurrently, regulatory and payer frameworks are evolving to better account for long-term outcomes, quality-of-life metrics, and the cost offsets associated with reduced postoperative morbidity. This regulatory maturation is accompanied by increased attention to scalability through manufacturing standardization and supply-chain resilience. As a result, manufacturers are prioritizing modular platform approaches and interoperability with surgical visualization tools, while clinical training programs emphasize reproducible techniques and outcomes monitoring. Collectively, these factors are converging to reshape competitive positioning and to expand the clinical utility of MIGS across diverse care settings.

Evaluating how the cumulative effect of 2025 tariff measures reshapes sourcing, manufacturing footprints, and procurement strategies for minimally invasive glaucoma device makers

The introduction of new tariff policies and trade measures in 2025 has introduced a material shock to the global supply chains that underpin medical-device production, with implications for components, raw materials, and subassembly sourcing. For MIGS devices, which rely on specialized metals such as nitinol and titanium as well as a range of polymeric materials, cumulative tariff effects create upward pressure on input costs and compel manufacturers to reassess sourcing strategies. As firms respond, many are accelerating supplier diversification, nearshoring of critical production steps, and vertical integration for high-value components to mitigate exposure to import taxes and cross-border logistical volatility.

These dynamics are not limited to procurement. Regulatory documentation and quality systems must adapt when manufacturing footprints change, potentially elongating time-to-market for iterations and new product introductions. In the clinical setting, cost pressures can translate into more rigorous evaluations of device selection, influencing hospital formulary decisions and contracting dynamics with ambulatory surgery centers and specialty hospitals. Consequently, organizations that proactively optimize procurement, engage in scenario-based pricing strategies, and invest in localized manufacturing capability are better positioned to preserve margins and sustain clinical adoption amid tariff-driven uncertainty.

A comprehensive segmentation-driven analysis connecting device typology, clinical indications, surgical approaches, materials, end users, and distribution channels to strategic priorities

A granular segmentation lens reveals nuanced opportunities and constraints that cut across product design, clinical positioning, and commercial strategy. By device type, the field encompasses Schlemm's canal scaffolds and expanders, subconjunctival microshunts, suprachoroidal microshunts, and trabecular bypass stents, the latter of which is differentiated between multi-stent systems and single-stent systems; each modality carries distinct efficacy profiles, implantation techniques, and evidence-generation pathways that influence adoption curves. When viewed by indication, clinical utility varies across angle-closure glaucoma, congenital glaucoma, primary open-angle glaucoma, and secondary glaucoma, requiring tailored clinical trials and labeling strategies to validate safety and effectiveness for specific patient cohorts.

Surgical approach segmentation separates ab externo from ab interno procedures, which has direct implications for required instrumentation, surgeon training, and intraoperative workflow. Procedure type further differentiates combined with cataract surgery interventions from standalone procedures, influencing perioperative planning and reimbursement coding. Material selection-metals versus polymers with metals subdivided into nitinol and titanium and polymers into gelatin/collagen, polyethersulfone, polyimide, and silicone-affects biocompatibility, durability, and manufacturing complexity, and therefore informs both regulatory strategy and supply-chain risk assessments. End-user segmentation across ambulatory surgery centers, ophthalmic clinics, and specialty eye hospitals highlights variance in purchasing behavior, volume thresholds, and clinical throughput, while distribution channel distinctions between offline and online influence pricing transparency and logistics. Integrated consideration of these dimensions enables companies to align product pipelines, clinical evidence generation, and commercialization tactics to the realities of adoption across different clinical and commercial contexts.

Regional dynamics and market-access considerations across Americas, Europe Middle East & Africa, and Asia-Pacific that inform regulatory, commercial, and operational strategies

Regional dynamics continue to shape product strategy, regulatory pathways, and commercial traction across the globe. In the Americas, regulatory rigor and established reimbursement frameworks enable earlier commercialization for devices supported by robust clinical evidence, and the prominence of ambulatory surgery centers creates an operational environment conducive to MIGS uptake. This region also tends to favor innovation that demonstrably reduces postoperative burden, making surgical ease-of-use and reproducible outcomes central to commercial success. Transitioning eastward, Europe, Middle East & Africa presents a mosaic of regulatory regimes, payer structures, and procurement practices; while some markets adopt harmonized regulatory standards that facilitate cross-border entry, others require localized clinical data and tailored costing models, which means commercial strategy must be regionally calibrated.

In Asia-Pacific, the market environment is characterized by a mix of advanced adoption in economies with high ophthalmic care capacity and rapid growth potential in emerging markets where expanding surgical infrastructure is enabling increased procedure volumes. Local manufacturing capabilities, government-driven healthcare investments, and distinct clinical practice patterns influence device selection and pricing dynamics. Across all regions, strategic partnerships with local distributors, investment in surgeon training, and sensitivity to procurement timelines are critical enablers for sustained market penetration and scale.

How competitive positioning, clinical evidence strategies, and strategic partnerships are defining leadership and differentiation among minimally invasive glaucoma device manufacturers

Competitive dynamics in the MIGS arena are shaped by the interplay of established medical-device manufacturers, ophthalmic-focused firms, and emergent startups pursuing differentiated technical approaches. Leading organizations emphasize robust clinical programs and post-market surveillance to substantiate comparative effectiveness and long-term safety, while smaller innovators leverage targeted niches-such as novel implant geometries, soft polymer materials, or delivery system ergonomics-to gain initial clinical traction. Strategic activity frequently centers on partnerships that accelerate distribution, co-development arrangements that consolidate surgical platforms, and selective acquisitions that expand portfolios to cover complementary procedural approaches.

Intellectual property protection, regulatory pathway expertise, and the ability to generate reproducible real-world evidence are recurring determinants of competitive advantage. Companies that invest in surgeon education, digital support tools for intraoperative guidance, and comprehensive outcomes registries not only shorten adoption cycles but also create defensible differentiation in a market where incremental product improvements can materially influence selection criteria. Going forward, the firms that most effectively integrate clinical data, surgeon workflows, and supply-chain resilience will define the leadership tier within the MIGS ecosystem.

Practical and prioritized strategic actions for manufacturers, health systems, and distributors to strengthen adoption, evidence generation, and supply-chain resilience in MIGS

Leaders in the MIGS ecosystem should pursue a set of actionable priorities that align clinical value with operational resilience. First, prioritize clinical evidence generation that addresses comparative effectiveness versus alternative surgical options and substantiates benefits in combined and standalone indications; this will strengthen discussions with payers and hospital formulary committees. Second, optimize supply chains through supplier diversification, consideration of localized manufacturing for high-risk components, and inventory strategies that reduce exposure to trade disruptions and tariff variability.

Third, invest in surgeon training and proctoring programs that shorten the learning curve for ab interno and ab externo approaches while demonstrating consistent outcomes across practice settings. Fourth, adopt pricing and contracting models that recognize the heterogeneity of end users, from ambulatory surgery centers to specialty hospitals, and enable flexible commercial engagement across offline and online distribution channels. Finally, cultivate partnerships with digital health vendors and imaging-platform providers to enhance intraoperative visualization and outcomes tracking, thereby creating integrated solutions that offer demonstrable clinical and economic value to payers and providers alike.

A transparent and evidence-based research methodology integrating primary expert interviews, systematic clinical review, and triangulation to validate strategic insights

This analysis synthesizes primary and secondary methodologies to ensure a balanced, evidence-informed perspective. Primary research included structured interviews with ophthalmic surgeons, hospital procurement leaders, and device development professionals to capture real-world insights into procedural preferences, device selection criteria, and supply-chain considerations. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, and publicly available procedural guidelines to triangulate efficacy, safety, and pathway requirements. Together, these approaches informed a layered understanding of both clinical and commercial dynamics.

To validate findings, cross-referencing of clinical outcomes with expert input and regulatory precedent was undertaken, and sensitivity checks were applied to qualitative inferences to reduce bias. Where appropriate, gaps in published evidence were mitigated by targeted follow-up interviews and by examining analogous device categories for transferable lessons. While every effort was made to ensure comprehensiveness, readers should recognize the evolving nature of clinical data and the potential for regulatory changes to alter the landscape; therefore, periodic reassessment is advisable to maintain strategic relevance.

A concise synthesis of strategic takeaways highlighting how evidence, commercialization, and operational resilience shape long-term success in MIGS

Minimally invasive glaucoma surgery devices represent a maturing but still rapidly evolving segment of ophthalmic care where incremental innovation, clinical evidence, and operational readiness converge to determine adoption trajectories. The interplay between device typology, surgical approach, material selection, and end-user settings creates a complex landscape that rewards specificity in clinical development and nimbleness in commercial execution. As supply-chain pressures and policy dynamics evolve, the capacity to adapt procurement, manufacturing, and training programs will increasingly separate resilient players from those exposed to disruption.

In sum, stakeholders that align rigorous evidence generation with targeted commercialization, proactive supply-chain risk management, and meaningful engagement with surgical communities will be best positioned to translate technological promise into durable clinical and commercial outcomes. Continuously updated intelligence and scenario planning are essential to anticipate shifts in regulation, reimbursement, and geopolitical influences that could affect market access and competitive advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minimally Invasive Glaucoma Surgery Devices Market, by Device Type

  • 8.1. Ablation Tools
  • 8.2. Catheter
  • 8.3. Lumen-Based Shunts
    • 8.3.1. Fixed-Lumen
    • 8.3.2. Flow-Controlled
  • 8.4. Scaffold/Expander
  • 8.5. Stents

9. Minimally Invasive Glaucoma Surgery Devices Market, by Surgical Site

  • 9.1. Ciliary Body
  • 9.2. Schlemm's Canal
  • 9.3. Subconjunctival Space
  • 9.4. Suprachoroidal Space
  • 9.5. Trabecular Meshwork

10. Minimally Invasive Glaucoma Surgery Devices Market, by Indication

  • 10.1. Angle-Closure Glaucoma
  • 10.2. Congenital Glaucoma
  • 10.3. Primary Open Angle Glaucoma
  • 10.4. Secondary Glaucoma

11. Minimally Invasive Glaucoma Surgery Devices Market, by Surgical Approach

  • 11.1. Ab Externo
  • 11.2. Ab Interno

12. Minimally Invasive Glaucoma Surgery Devices Market, by Procedure Type

  • 12.1. Combined With Cataract Surgery
  • 12.2. Standalone Procedure

13. Minimally Invasive Glaucoma Surgery Devices Market, by Implant Material

  • 13.1. Metals
    • 13.1.1. Nitinol
    • 13.1.2. Titanium
  • 13.2. Polymers
    • 13.2.1. Gelatin
    • 13.2.2. Polyethersulfone
    • 13.2.3. Polyimide
    • 13.2.4. Silicone

14. Minimally Invasive Glaucoma Surgery Devices Market, by Device Class

  • 14.1. Implantable
  • 14.2. Non-implantable

15. Minimally Invasive Glaucoma Surgery Devices Market, by Payment Method

  • 15.1. Reimbursement-Based
  • 15.2. Self-Pay

16. Minimally Invasive Glaucoma Surgery Devices Market, by Patient Type

  • 16.1. Pediatric
  • 16.2. Adult

17. Minimally Invasive Glaucoma Surgery Devices Market, by Usability

  • 17.1. Reusable
  • 17.2. Disposable

18. Minimally Invasive Glaucoma Surgery Devices Market, by End User

  • 18.1. Ambulatory Surgery Centers
  • 18.2. Ophthalmic Clinics
  • 18.3. Specialty Eye Hospitals

19. Minimally Invasive Glaucoma Surgery Devices Market, by Distribution Channel

  • 19.1. Offline
  • 19.2. Online

20. Minimally Invasive Glaucoma Surgery Devices Market, by Region

  • 20.1. Americas
    • 20.1.1. North America
    • 20.1.2. Latin America
  • 20.2. Europe, Middle East & Africa
    • 20.2.1. Europe
    • 20.2.2. Middle East
    • 20.2.3. Africa
  • 20.3. Asia-Pacific

21. Minimally Invasive Glaucoma Surgery Devices Market, by Group

  • 21.1. ASEAN
  • 21.2. GCC
  • 21.3. European Union
  • 21.4. BRICS
  • 21.5. G7
  • 21.6. NATO

22. Minimally Invasive Glaucoma Surgery Devices Market, by Country

  • 22.1. United States
  • 22.2. Canada
  • 22.3. Mexico
  • 22.4. Brazil
  • 22.5. United Kingdom
  • 22.6. Germany
  • 22.7. France
  • 22.8. Russia
  • 22.9. Italy
  • 22.10. Spain
  • 22.11. China
  • 22.12. India
  • 22.13. Japan
  • 22.14. Australia
  • 22.15. South Korea

23. United States Minimally Invasive Glaucoma Surgery Devices Market

24. China Minimally Invasive Glaucoma Surgery Devices Market

25. Competitive Landscape

  • 25.1. Market Concentration Analysis, 2024
    • 25.1.1. Concentration Ratio (CR)
    • 25.1.2. Herfindahl Hirschman Index (HHI)
  • 25.2. Recent Developments & Impact Analysis, 2024
  • 25.3. Product Portfolio Analysis, 2024
  • 25.4. Benchmarking Analysis, 2024
  • 25.5. AbbVie Inc.
  • 25.6. Alcon Vision LLC
  • 25.7. Bausch + Lomb Corp.
  • 25.8. BVI Medical, Inc.
  • 25.9. Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • 25.10. Glaukos Corporation
  • 25.11. Haag-Streit Group by Metall Zug AG
  • 25.12. Iridex Corporation
  • 25.13. iSTAR Medical
  • 25.14. Johnson & Johnson Services, Inc.
  • 25.15. Lumibird Medical
  • 25.16. New World Medical, Inc.
  • 25.17. Nova Eye Medical Limited
  • 25.18. Oertli Instrumente AG
  • 25.19. Santen Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL SITE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PAYMENT METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY USABILITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 20. CHINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ABLATION TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ABLATION TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ABLATION TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY FIXED-LUMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY FIXED-LUMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY FIXED-LUMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY FLOW-CONTROLLED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY FLOW-CONTROLLED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY FLOW-CONTROLLED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SCAFFOLD/EXPANDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SCAFFOLD/EXPANDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SCAFFOLD/EXPANDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL SITE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CILIARY BODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CILIARY BODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CILIARY BODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SCHLEMM'S CANAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SCHLEMM'S CANAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SCHLEMM'S CANAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL SPACE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL SPACE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL SPACE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SPACE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SPACE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SPACE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MESHWORK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MESHWORK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MESHWORK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ANGLE-CLOSURE GLAUCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ANGLE-CLOSURE GLAUCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ANGLE-CLOSURE GLAUCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CONGENITAL GLAUCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CONGENITAL GLAUCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY CONGENITAL GLAUCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRIMARY OPEN ANGLE GLAUCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRIMARY OPEN ANGLE GLAUCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRIMARY OPEN ANGLE GLAUCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SECONDARY GLAUCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SECONDARY GLAUCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SECONDARY GLAUCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB EXTERNO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB EXTERNO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB EXTERNO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB INTERNO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB INTERNO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB INTERNO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COMBINED WITH CATARACT SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COMBINED WITH CATARACT SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COMBINED WITH CATARACT SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STANDALONE PROCEDURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STANDALONE PROCEDURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STANDALONE PROCEDURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY NITINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY NITINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY NITINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TITANIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TITANIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TITANIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY GELATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY GELATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYIMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYIMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYIMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY NON-IMPLANTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY NON-IMPLANTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY NON-IMPLANTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PAYMENT METHOD, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REIMBURSEMENT-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REIMBURSEMENT-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REIMBURSEMENT-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SELF-PAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SELF-PAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SELF-PAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY USABILITY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISPOSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISPOSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SPECIALTY EYE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SPECIALTY EYE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SPECIALTY EYE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL SITE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PAYMENT METHOD, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY USABILITY, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL SITE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PAYMENT METHOD, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY USABILITY, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL SITE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PAYMENT METHOD, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY USABILITY, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL SITE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PAYMENT METHOD, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY USABILITY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL SITE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PAYMENT METHOD, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY USABILITY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL SITE, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PAYMENT METHOD, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY USABILITY, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL SITE, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PAYMENT METHOD, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY USABILITY, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY LUMEN-BASED SHUNTS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL SITE, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY METALS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DEVICE CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC MI